LU85616A1 - Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci - Google Patents

Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci Download PDF

Info

Publication number
LU85616A1
LU85616A1 LU85616A LU85616A LU85616A1 LU 85616 A1 LU85616 A1 LU 85616A1 LU 85616 A LU85616 A LU 85616A LU 85616 A LU85616 A LU 85616A LU 85616 A1 LU85616 A1 LU 85616A1
Authority
LU
Luxembourg
Prior art keywords
prazosin hydrochloride
anhydrous
crystalline form
stable
chosen
Prior art date
Application number
LU85616A
Other languages
English (en)
French (fr)
Inventor
Stig Olof Engelbert Lindholm
Original Assignee
Orion Yhtymae Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtymae Oy filed Critical Orion Yhtymae Oy
Publication of LU85616A1 publication Critical patent/LU85616A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LU85616A 1984-06-25 1984-10-29 Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci LU85616A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI842544 1984-06-25
FI842544A FI79107C (fi) 1984-06-25 1984-06-25 Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.

Publications (1)

Publication Number Publication Date
LU85616A1 true LU85616A1 (fr) 1985-06-04

Family

ID=8519293

Family Applications (1)

Application Number Title Priority Date Filing Date
LU85616A LU85616A1 (fr) 1984-06-25 1984-10-29 Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci

Country Status (17)

Country Link
US (2) US4739055A (de)
JP (1) JPS6115881A (de)
AT (1) AT389117B (de)
AU (1) AU566814B2 (de)
BE (1) BE900925A (de)
CH (1) CH661045A5 (de)
DE (1) DE3429415A1 (de)
FI (1) FI79107C (de)
FR (1) FR2567124B1 (de)
GB (1) GB2160861B (de)
IL (1) IL73267A (de)
IT (1) IT1224142B (de)
LU (1) LU85616A1 (de)
NL (1) NL8403250A (de)
NZ (1) NZ209962A (de)
PT (1) PT79411B (de)
ZA (1) ZA85910B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608A1 (de) * 1986-03-21 1987-09-23 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2756846B2 (ja) * 1989-12-28 1998-05-25 住化ファインケム株式会社 無水のε型結晶体2―〔4―(2―フロイル)ピペラジン―1―イル〕―4―アミノ―6,7―ジメトキシキナゾリン塩酸塩及びその製造方法
JPH07206857A (ja) * 1993-12-28 1995-08-08 Synthelabo Sa アルフゾシン塩酸塩の二水和物
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
EP3542801A1 (de) * 2007-08-17 2019-09-25 Boehringer Ingelheim International GmbH Purinderivate zur verwendung bei der behandlung von fap-bedingten erkrankungen
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
PE20110297A1 (es) * 2008-08-15 2011-05-26 Boehringer Ingelheim Int Inhibidores de dpp-4 para la cicatrizacion de heridas
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3366304B1 (de) 2010-06-24 2020-05-13 Boehringer Ingelheim International GmbH Diabetestherapie
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013010964A1 (en) 2011-07-15 2013-01-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP3468562A1 (de) 2016-06-10 2019-04-17 Boehringer Ingelheim International GmbH Kombinationen aus linagliptin und metformin

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2969375A (en) * 1961-01-24 Certification of correction
DE156532C (de) *
NL54420C (de) * 1937-05-25
GB1156973A (en) * 1965-07-06 1969-07-02 Quinazoline Derivatives
US3433788A (en) * 1966-04-27 1969-03-18 Union Carbide Corp Process for recovery of amines from aqueous solutions by solvent treatment and distillation
US3421983A (en) * 1967-03-07 1969-01-14 Lummus Co Azeotropic distillation of aqueous toluene diamine
US3511836A (en) * 1967-12-13 1970-05-12 Pfizer & Co C 2,4,6,7-tetra substituted quinazolines
US3743672A (en) * 1970-05-27 1973-07-03 Halcon International Inc Separation of water in alkylene glycol mono and diester purification by azeotropic distillation
GB1308718A (en) * 1970-07-01 1973-03-07 Sir Soc Italiana Resine Spa Method of separating vinyl acetate from liquid mixtures
IT956765B (it) * 1972-06-22 1973-10-10 Montedison Spa Procedimento per la purificazione di 1 3 diossolano
US3935213A (en) * 1973-12-05 1976-01-27 Pfizer Inc. Process for hypotensive 4-amino-2-(piperazin-1-yl) quinazoline derivatives
US4026894A (en) * 1975-10-14 1977-05-31 Abbott Laboratories Antihypertensive agents
US4001237A (en) * 1976-02-18 1977-01-04 Bristol-Myers Company Oxazole, isoxazole, thiazole and isothiazole amides
US4092315A (en) * 1976-03-01 1978-05-30 Pfizer Inc. Novel crystalline forms of prazosin hydrochloride
FI67699C (fi) * 1979-01-31 1985-05-10 Orion Yhtymae Oy Foerfarande foer framstaellning av 6,7-dimetoxi-4-amino-2-(4-(2-furoyl)-1-piperazinyl)kinazolinhydroklorid med blodtryckssaenkande verkan
FI64367C (fi) * 1980-02-26 1986-08-05 Orion Yhtymae Oy Foerfarande foer framstaellning av alfa-form av prazosinhydroklorid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237608A1 (de) * 1986-03-21 1987-09-23 HEUMANN PHARMA GMBH & CO Kristalline, wasserfreie Sigma -Form von 2-[4-(2-Furoyl-(2-piperazin)-1-yl]-4-amino-6,7-dimethoxychinazolinhydrochlorid und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
GB2160861A (en) 1986-01-02
US4873330A (en) 1989-10-10
IL73267A0 (en) 1985-01-31
FI842544A0 (fi) 1984-06-25
PT79411A (en) 1984-11-01
JPS6115881A (ja) 1986-01-23
FI79107B (fi) 1989-07-31
DE3429415A1 (de) 1986-01-02
IT1224142B (it) 1990-09-26
ZA85910B (en) 1985-09-25
BE900925A (fr) 1985-02-15
GB8424999D0 (en) 1984-11-07
ATA344184A (de) 1989-03-15
FR2567124A1 (fr) 1986-01-10
FR2567124B1 (fr) 1990-09-21
CH661045A5 (de) 1987-06-30
GB2160861B (en) 1987-11-18
IL73267A (en) 1988-06-30
US4739055A (en) 1988-04-19
IT8423292A0 (it) 1984-10-24
AU566814B2 (en) 1987-10-29
FI842544A (fi) 1985-12-26
AU3451084A (en) 1986-01-02
AT389117B (de) 1989-10-25
FI79107C (fi) 1989-11-10
NL8403250A (nl) 1986-01-16
NZ209962A (en) 1987-06-30
PT79411B (en) 1986-09-15
JPH0481993B2 (de) 1992-12-25
DE3429415C2 (de) 1990-05-03

Similar Documents

Publication Publication Date Title
LU85616A1 (fr) Nouvelle forme cristalline delta;anhydre et stable,du chlorhydrate de prazosine et nouveau procede de fabrication de celle-ci
EP0210084B1 (de) Amide, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP2185543B1 (de) Verfahren zur optischen trennung von omeprazol-salzen
EP1403266B1 (de) Verfahren zur industriellen Herstellung von Strontiumranelat und seinen Hydraten
FR2663934A1 (fr) Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.
EP2595976A1 (de) Verfahren zur herstellung von aminobenzoylbenzofuranderivaten
WO2013079866A1 (fr) Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP0382634A1 (de) Pyridazin-Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammenstellungen
EP0309324A1 (de) Verfahren zur Herstellung von N-alkylierten Aminosäuren und deren Estern, Verwendung zur Synthese von Carboxyalkyldipeptiden
EP0495709A1 (de) Aryltriazinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die sie enthalten
FR2793490A1 (fr) Procede de preparation du (1r,2s,4r)-(-)-2-[(2'-{n,n- dimethylamino}-ethoxy)]-2-[phenyl]-1,7,7-tri-[methyl]- bicyclo[2.2.1]-heptane et ses sels d'addition d'acide pharmaceutiquement acceptables
EP0612716B1 (de) Verfahren zur Herstellung von einem optisch reinen Aminoalkohol
FR2689889A1 (fr) Nouveaux dérivés de perhydroisoindole, et leur préparation.
EP0240398A1 (de) Dissymmetrische 1,4-Dihydropyridin-3,5-dicarbonsäure-Derivate, Verfahren zur Herstellung und Verwendung in Therapeutik
EP0708759B1 (de) Verfahren zu herstellung von substituierten pyrazinen
EP0294258A1 (de) Hydrazin-Derivate, Verfahren zu deren Erhaltung und diese enthaltende pharmazeutische Zusammensetzungen
CH594650A5 (en) Antiinflammatory (1,2)-benzothiazine derivs. prepn.
CA1129886A (fr) Procede de preparation de n-alcoylamino benzophenones
FR2565972A1 (fr) Preparation des derives d'amines
JP4664903B2 (ja) 4,10β−ジアセトキシ−2α−ベンゾイルオキシ−5β,20−エポキシ−1,13α−ジヒドロキシ−9−オキソ−19−ノルシクロプロパ[g]タキサ−11−エンの製造方法
EP1214309B8 (de) Herstellung von amimide abgeleitet von 6-hydroxy-2,5,7,8-tetramethylchroman-2-säure
EP0003456A1 (de) 3-Amino-cardenolidderivate, Verfahren zu ihrer Herstellung und Arzneimittel, die diese enthalten
CH624094A5 (en) Process for the preparation of 5-amino-2-propargyloxy-N-n-butylbenzamide
CZ45193A3 (en) Salts of (r)-4-nitro-alphamethyl benzene methaneamine
WO2004035584A1 (fr) Composes pharmaceutiques inhibiteurs specifiques de la pde5 du muscle lisse, compositions pharmaceutiques les contenant et utilisations therapeutiques